Search

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Splenic marginal zone lymphoma study update, February 2024

A project update from Dr Ahmed Ludvigsen Al-Mashhadi. I am truly grateful for this opportunity provided by EHA, and for EHA's effort in advancing research in a field that may otherwise be very difficult to explore.

Read more

National societies

EHA pursues close collaboration with the national hematology societies to ensure that the professional hematology community in Europe is served in the best possible way.

Read more

Healthcare-affiliated professional membership

You don't need to be scientific researcher or a physician to join our vibrant community.

Read more

Specialized Working Group Grants

The call for grant proposals closed at 12:00 on November 30, 2024. EHA provides financial support to small research projects initiated by our specialized working groups (SWGs).

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more